FDA grants fast-track approval for Novo Nordisk obesity drug

The U.S. Food and Drug Administration has granted accelerated approval to a new obesity treatment from Novo Nordisk, giving the Danish drugmaker another major regulatory win in a fast-growing market.

The decision marks a key step in the company’s effort to expand its pipeline beyond its established diabetes and weight-loss portfolio. Accelerated approval is typically reserved for treatments that address serious conditions and can speed access to promising therapies while additional evidence is collected.

Novo Nordisk has become one of the most closely watched names in the pharmaceutical industry as demand for obesity medicines surges worldwide. The latest approval adds to investor and public health attention on how quickly the company can scale production and broaden treatment options.

The move also underscores the FDA’s willingness to use expedited pathways for drugs that may help meet urgent medical needs, even as regulators continue to monitor safety, long-term outcomes and real-world effectiveness.